Antitumor effect of the selective cyclooxygenase-2 inhibitor on bone and soft tissue sarcomas.

2014 Fiscal Year Final Research Report

• Project/Area Number: 25861331
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Orthopaedic surgery
• Research Institution: Fukushima Medical University
• Principal Investigator: HAKOZAKI Michiyuki 福島県立医科大学, 医学部, 准教授 (10583651)
• Co-Investigator(Renkei-kenkyūsha): HOJO Hiroshi 福島県立医科大学, 会津医療センター, 教授 (90209213) ; ABE Masafumi 福島県立医科大学, 副学長 (00045783) ; KONNO Shinichi 福島県立医科大学, 医学部, 教授 (70254018) ; KIKUCHI Shinichi 福島県立医科大学, 学長 (80045773)
• Research Collaborator: TAJINO Takahiro 福島県立医科大学, 医学部, 客員教授 ; YAMADA Hitoshi 福島県立医科大学, 医学部, 講師 ; TAMURA Hirosumi 福島県立医科大学, 医療-産業トランスレーショナルリサーチセンター, 助教 ; YANAGISAWA Michiro 弘前大学, 医学部 ; NISHIDA Jun 東京医科大学, 医学部 ; NAGASAWA Hiroyuki 秋田大学, 医学部 ; TSUCHIYA Takashi 山形大学, 医学部 ; OGOSE Akira 新潟大学, 医歯学総合病院
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: 骨軟部肉腫 / 悪性骨軟部腫瘍 / 分子標的治療 / 腫瘍細胞株 / 選択的シクロオキシゲナーゼ-2阻害薬

Outline of Final Research Achievements

The purpose of this study was to investigate a potential therapeutic role of ｃyclooxygenase-2 (COX-2) in bone and soft-tissue sarcomas.
In malignant peripheral nerve sheath tumor (MPNST), a rare and aggressive soft tissue sarcoma, overexpression of COX-2 was observed in 65.9%, was significantly associated with a poor overall survival, and was considered an independent risk factor for a poor outcome by the results of both univariate and multivariate analysis. Moreover, the selective COX-2 inhibitor etodolac induced apoptosis of MPNST cells through the activation of caspase-8, -9, and -3.
Selective COX-2 inhibitors including etodolac had an antitumor effect on MPNST cells, and their use holds promise as a novel therapeutic strategy for patients with MPNST to improve their prognoses.

Free Research Field

骨軟部腫瘍